MiR-503 targets PI3K p85 and IKK-β and suppresses progression of non-small cell lung cancer

International Journal of Cancer

Volumn 135, Issue 7, 2014, Pages 1531-1542

  Yang, Yi ^a,b   Liu, Lei ^a,b   Zhang, Ying ^b   Guan, Hongyu ^c   Wu, Jueheng ^a,b   Zhu, Xun ^a,b   Yuan, Jie ^a,b   Li, Mengfeng ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

IKK ; lung cancer; miR 503; PI3K p85

Indexed keywords

ANTIMETASTATIC AGENT; I KAPPA B BETA; MICRORNA; MICRORNA 503; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P85; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALE; METASTASIS INHIBITION; MIDDLE AGED; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL;

IKK-Β; LUNG CANCER; MIR-503; PI3K P85;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; I-KAPPA B KINASE; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; LUCIFERASES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; WOUND HEALING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904459866     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28799     Document Type: Article

References (47)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-917.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Spira A, Ettinger DS,. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350: 379-92.
4. Zhang WC, Shyh-Chang N, Yang H, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 2012; 148: 259-72.
5. Cataldo VD, Gibbons DL, Perez-Soler R, et al. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011; 364: 947-55.
6. Moran C,. Importance of molecular features of non-small cell lung cancer for choice of treatment. Am J Pathol 2011; 178: 1940-8.
7. Bartel DP,. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-33.
8. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
9. He M, Xu Z, Ding T, et al. MicroRNA-155 regulates inflammatory cytokine production in tumor-associated macrophages via targeting C/EBPbeta. Cell Mol Immunol 2009; 6: 343-52.
10. Mendell JT,. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle 2005; 4: 1179-84.
11. Caporali A, Emanueli C,. MicroRNA-503 and the extended microRNA-16 family in angiogenesis. Trends Cardiovasc Med 2011; 21: 162-6.
12. Lu YC, Chen YJ, Wang HM, et al. Oncogenic function and early detection potential of miRNA-10b in oral cancer as identified by microRNA profiling. Cancer Prev Res (Phila) 2012; 5: 665-74.
13. Zhou B, Ma R, Si W, et al. MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer Lett 2013; 333: 159-69.
14. Xu YY, Wu HJ, Ma HD, et al. MicroRNA-503 suppresses proliferation and cell-cycle progression of endometrioid endometrial cancer by negatively regulating cyclin D1. FEBS J 2013; 280: 3768-79.
15. Ozata DM, Caramuta S, Velazquez-Fernandez D, et al. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer 2011; 18: 643-55.
16. Tombol Z, Szabo PM, Molnar V, et al. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocr Relat Cancer 2009; 16: 895-906.
17. Zhao JJ, Yang J, Lin J, et al. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst 2009; 25: 13-20.
18. Sarkar S, Dey BK, Dutta A,. MiR-322/424 and -503 are induced during muscle differentiation and promote cell cycle quiescence and differentiation by down-regulation of Cdc25A. Mol Biol Cell 2010; 21: 2138-49.
19. Jiang Q, Feng MG, Mo YY,. Systematic validation of predicted microRNAs for cyclin D1. BMC Cancer 2009; 9: 194.
20. Zhou J, Wang W,. Analysis of microRNA expression profiling identifies microRNA-503 regulates metastatic function in hepatocellular cancer cell. J Surg Oncol 2011; 104: 278-83.
21. Ibrahim L, Dominguez M, Yacoub M,. Primary human adult lung epithelial cells in vitro: response to interferon-gamma and cytomegalovirus. Immunology 1993; 79: 119-24.
22. Boffa DJ, Detterbeck FC, Smith EJ, et al. Should the 7th edition of the lung cancer stage classification system change treatment algorithms in non-small cell lung cancer? J Thorac Oncol 2010; 5: 1779-83.
23. Cai J, Wu J, Zhang H, et al. miR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation. Cancer Res 2013; 73: 756-66.
24. Yang Y, Wu J, Guan H, et al. MiR-136 promotes apoptosis of glioma cells by targeting AEG-1 and Bcl-2. FEBS Lett; 2012; 586: 3608-12.
25. Guan H, Song L, Cai J, et al. Sphingosine kinase 1 regulates the Akt/FOXO3a/Bim pathway and contributes to apoptosis resistance in glioma cells. PLoS One 2011; 6: e19946.
26. Jiang L, Lin C, Song L, et al. MicroRNA-30e* promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-kappaB/IkappaBalpha negative feedback loop. J Clin Invest 2012; 122: 33-47.
27. Subramanian J, Govindan R,. Lung cancer in never smokers: a review. J Clin Oncol 2007; 25: 561-70.
28. Travis WD, Travis LB, Devesa SS,. Lung cancer. Cancer 1995; 75: 191-202.
29. Vleminckx K, Vakaet L, Jr, Mareel M, et al. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991; 66: 107-19.
30. Qiu T, Zhou L, Wang T, et al. miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2. Int J Mol Med 2013; 32: 593-8.
31. Park YT, Jeong JY, Lee MJ, et al. MicroRNAs overexpressed in ovarian ALDH1-positive cells are associated with chemoresistance. J Ovarian Res 2013; 6: 18.
32. Park SY, Lee JH, Ha M, et al. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009; 16: 23-9.
33. Lin X, Bohle AS, Dohrmann P, et al. Overexpression of phosphatidylinositol 3-kinase in human lung cancer. Langenbecks Arch Surg 2001; 386: 293-301.
34. Zito CR, Jilaveanu LB, Anagnostou V, et al. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One 2012; 7: e31331.
35. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-96.
36. Hu MC, Lee DF, Xia W, et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004; 117: 225-37.
37. Baumgartner B, Weber M, Quirling M, et al. Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. Leukemia 2002; 16: 2062-71.
38. Li L, Aggarwal BB, Shishodia S, et al. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004; 101: 2351-62.
39. Ludwig L, Kessler H, Wagner M, et al. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res 2001; 61: 4526-35.
40. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, et al. Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer. Cancer Res 2001; 61: 3810-18.
41. Yang J, Richmond A,. Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res 2001; 61: 4901-9.
42. Maeda S, Kamata H, Luo JL, et al. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121: 977-90.
43. Kim S, Jung JK, Lee HS, et al. Discovery of piperidinyl aminopyrimidine derivatives as IKK-2 inhibitors. Bioorg Med Chem Lett 2011; 21: 3002-6.
44. Zhou BP, Liao Y, Xia W, et al. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001; 3: 245-52.
45. Javelaud D, Wietzerbin J, Delattre O, et al. Induction of p21Waf1/Cip1 by TNFalpha requires NF-kappaB activity and antagonizes apoptosis in Ewing tumor cells. Oncogene 2000; 19: 61-8.
46. Wuerzberger-Davis SM, Chang PY, Berchtold C, et al. Enhanced G2-M arrest by nuclear factor-{kappa}B-dependent p21waf1/cip1 induction. Mol Cancer Res 2005; 3: 345-53.
47. Julien S, Puig I, Caretti E, et al. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 2007; 26: 7445-56.